Simlandi is not covered on the Reformulary. Reformulary covers 4 preferred adalimumab biosimilars that offer the same clinical value at a lower net cost to the plan. AMGEVITA, HULIO, HADLIMA and YUFLYMA require Special Authorization.

Simlandi is used to treat  
Ankylosing Spondylitis
Hidradenitis Suppurativa
Inflammatory Bowel Disease (IBD)
Juvenile Idiopathic Arthritis
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Uveitis